The Efficacy and Safety of Endovascular Therapy for Acute Ischemic Stroke Due to Large Core Infar… (NCT07333950) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
The Efficacy and Safety of Endovascular Therapy for Acute Ischemic Stroke Due to Large Core Infarction
China308 participantsStarted 2026-01-01
Plain-language summary
This study assesses the efficacy and safety of endovascular therapy in patients with acute basilar artery occlusion with large core infarction within a multicenter, prospective, open-label, blinded endpoint, randomized controlled trial
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. The age ranged from 18 to 80 years
✓. Acute ischemic stroke in posterior circulation, the time from stroke onset (or finally found normal) to randomization was within 24 hours
✓. Acute basilar artery occlusion confirmed by CTA,MRA,or DSA
✓. Posterior circulation large core infarction:NCCT or DWI showed pc-ASPECTS≤5, or Pons-Midbrain Index (PMI)≥3
✓. NIHSS score ≥10 before randomization
✓. Pre-stroke mRS of 0-2
✓. Each patient or their legal representative must provide written informed consent before enrolment
Exclusion criteria
✕. Any sign of intracranial hemorrhage (except microbleeds) on brain imaging prior to randomization
✕. Complete cerebellar infarct with significant mass effect, or bilateral thalamic infarction as evidenced by baseline neuroimaging
✕. Known or highly suspected chronic occlusion of basilar artery
✕. History of contraindication for contrast medium (except mild rash)
✕. Current pregnant or breast-feeding
✕. Refractory hypertension (defined as systolic blood pressure\>220 mmHg or diastolic blood pressure\>110 mmHg) that cannot be controlled by drug treatment;
What they're measuring
1
Rate of modified Rankin scale 0-3 at 90 (±14) days after randomization